Newsletter Subject

A Few Phrases I Never Say to Patients

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Sat, Apr 13, 2024 11:17 AM

Email Preheader Text

Weekly Review Saturday, April 13, 2024 THE BREAK ROOM CME SPOTLIGHT THE BREAK ROOM ADVERTISEMENT CME

[MEDPAGE TODAY]( Weekly Review Saturday, April 13, 2024 [A Few Phrases I Never Say to Patients]( [Doc's Murderer Imprisoned; Butt Injection Arrest; Free Botox for Sex]( [Here's Why Nurses Are Exiting Healthcare]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Optimizing Treatment With Infusion-Based Therapies for HR+/HER2- and Triple-Negative Breast Cancer]( [CDC: COVID Vax Not Linked to Sudden Deaths in Young Adults]( [Here's a Good Exercise Option for Hip OA]( THE BREAK ROOM [Play Today's Wordosis: Our Medical Word Game]( ADVERTISEMENT [Cass Review Finds Weak Evidence for Puberty Blockers, Hormones in Youth Gender Care]( CME SPOTLIGHT [Optimizing the Management of Patients With mCRPC in Rural Communities: A Project ECHO Initiative]( [Can You Guess Which New EPA Rule Offers $13 Billion in Annual Health Benefits?]( [The Dying Brain; Obesity Drugs and MS; NurOwn Tries Again]( [Senator Scrutinizes Physician Staffing Firms and Their Private Equity Owners]( CME SPOTLIGHT [Improving Real-World Care For Veteran Patients With Hepatocellular Carcinoma: Strategies for Patient-Centered, Teams-Based Approaches]( [More Health Systems Likely to Drop Out of Medicare Advantage, Analyst Predicts]( [Self-Selection for Statin Appears Safe, Effective]( [Study Assuages Thyroid Cancer Fears With GLP-1 Receptor Agonists]( CME SPOTLIGHT [Expert Insights and System-Based Care Trends in Early-Stage NSCLC and Melanoma, Metastatic Bladder Cancer, and Relapsed/Refractory Follicular Lymphoma]( [FDA OKs Anxiety Stimulation Device; Long-Term KarXT Data; Psilocybin Adverse Events]( [Anti-DEI Initiatives in Medicine Harm Us All]( [Francis Collins Discloses His 'Aggressive' Prostate Cancer Diagnosis]( CME SPOTLIGHT [Latest Clinical Evidence in Adult Diffuse Low-Grade Glioma]( [Early Win for Preemptive Stents on Vulnerable Coronary Plaque]( [No, a Jail Is Not an Opioid Use Disorder Treatment Facility]( [Radial Cath Kits Recalled; siRNAs for Lipid Lowering; Smartphone HF Detection]( CME SPOTLIGHT [Applying the Latest Clinical Evidence to Treatment Plans for Pediatric Patients With Hodgkin Lymphoma]( ['Best Medical Schools' Rankings Delayed for Second Year in a Row]( [Type D Personality and Hypothyroidism; Infertility and eGFR; Fracture Algorithm]( [Riding the 'Boob Bus'; Prior Authorization Pushback; Cancer Warning for Alcohol?]( CME SPOTLIGHT [Employing Collaborative Care Strategies for the Management of Pediatric Patients With Hodgkin Lymphoma]( [Proof of Benefit in Acute MI Again Evades an SGLT2 Inhibitor]( [MedPod Today: Anti-DEI Rep at Med Meeting; Private Equity Probe; Delayed Rankings]( ['She Felt Like She Was Buying Toilet Paper During COVID': What We Heard This Week]( CME SPOTLIGHT [PARP Prodigy: Mastering Metastatic Castration-Resistant Prostate Cancer]( [What Patients Should Know Before Agreeing to Psychedelic Therapy]( [Laughter Is the Best Medicine]( [Here's What Medicaid Expansion Can Do for the Health of Your State]( [Can Machine Learning Predict CVD Risk? Sleep-Related Benefits of Exercise]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_DHE_Weekly?xid=nl_mpt_DHE_2024-04-13&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

13/05/2024

Sent On

12/05/2024

Sent On

12/05/2024

Sent On

11/05/2024

Sent On

10/05/2024

Sent On

10/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.